Current Concepts in the Treatment of Prostate Cancer

  title={Current Concepts in the Treatment of Prostate Cancer},
  author={A. J. Melamed},
  journal={Annals of Pharmacotherapy},
  pages={247 - 254}
Carcinoma of the prostate is one of the most common cancers in men over 50 years of age and is the second leading cause of cancer death in men over 75. As a general rule, symptoms usually are not apparent until the tumor is far advanced. Between 80 to 90 percent of patients have metastatic disease at the time of presentation and are not curable by surgery. Endocrine manipulation remains the most effective and commonly used treatment for metastatic carcinoma of the prostate. 

Figures, Tables, and Topics from this paper

The Potential Application of Finasteride for Chemoprevention of Prostate Cancer
A 5a-reductase inhibitor has the potential to suppress the formation of dihydrotestosterone (DHT), an important promoter of prostate cancer, with minimal toxicity and therefore satisfies these criteria. Expand
Chemoprevention strategies for prostate cancer: The role of 5α‐reductase inhibitors
5α‐reductase inhibitors have been shown to suppress serum and intraprostatic levels of dihydrotestosterone, an important promoter of prostate cancer, leading to reduction in prostate size and suppression of glandular cell activity as measured by prostate specific antigen secretion. Expand
Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
The results demonstrate that I3C represses AR expression and responsiveness in LNCaP cells as a part of its antiproliferative mechanism. Expand
Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer
A series of experiments were conducted to evaluate the effects of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer, and decreased the weight of the prostate in tumor‐bearing animals. Expand
Prostate Cancer Chemoprevention
Finasteride is a specific inhibitor of the Type 2 isoenzyme, and effectively blocks the Type 1-mediated conversion of testosterone to DHT, but does not inhibit the binding of DHT to the androgen receptor (AR). Expand
Radical Retropublic Prostatectomy


Hormonal therapy for prostate cancer.
  • F. Torti
  • Medicine
  • The New England journal of medicine
  • 1984
Most patients with a diagnosis of prostate cancer already have metastases or will have them despite treatment aimed at the primary tumor in the prostate gland, making prostatic cancer the tumor most responsive to hormonal therapy. Expand
Prognosis in patients with carcinoma of the prostate
Records of patients with carcinoma of the prostate admitted to the Hospital of the University of Pennsylvania over a 10‐year period were reviewed, and Histologic type, stage, and age of presentation seemed to be important in prognosis, while acid phosphatase level, race, and length of symptoms before diagnosis, except for localized lesions, were not. Expand
Endocrine and Cytotoxic Therapy
A disease common enough to account for 6% of all malignant disease in the male inevitably merits serious consideration and committed research programmes. The full impact of prostatic cancer is toExpand
Hormonal Aspects of Prostatic Cancer: A Review
  • J. Waxman
  • Medicine
  • Journal of the Royal Society of Medicine
  • 1985
As will be demonstrated, hormonal therapies are disparate and the rationale for response obscure, and the nature of this variation is complex. Expand
Conservative treatment of carcinoma of the prostate.
The case records of 1,560 patients who had carcinoma of the prostate were reviewed and five patients in whom metastasis had occurred were strikingly benefited by orchiectomy and/or diethylstilbestrol by mouth. Expand
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy. Expand
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
  • I. Tannock
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1985
There is little evidence that chemotherapy provides palliation for patients with prostatic carcinoma, and it should not be regarded as part of standard management. Expand
Carcinoma of prostate. Correlation between radiologic quantitation of metastases and patient survival.
A radiologic method of measuring metastases was developed and statistically analyzed with respect to survival based on 103 patients with known metastases at diagnosis. The analysis revealed aExpand
The veterans administration cooperative urological research group's studies of cancer of the prostate
The overall recommendation at present is that patients with prostatic cancer should not be treated until their symptoms require relief, and at that time it is recommended starting treatment with 1.0 mg DES daily. Expand
Endocrine and clinical effects of leuprolide in prostatic cancer
Except for vasomotor hot flashes, leuprolide appears to be well tolerated by patients with advanced prostatic cancer. Expand